Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRAVI: Transcriptomic Signature in Vitiligo
NCT05927272Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of methylprednisolone in nonsegmental vitiligo (NSV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Evaluate the evolution of skin biological pathways, assessed by single cell RNAseq in the peri-lesional and lesional skin of a target lesion at Month 6. Started Apr 2024; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT05927272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927272.